Пневмонии на фоне фармакологической иммуносупрессии: особенности этиологической диагностики: ПЕДИАТРИЯ

Екатерина Александровна  Хузина; Евгений Григорьевич  Фурман; Анастасия Алексеевна  Кильдибекова

doi:10.56871/

Пневмонии на фоне фармакологической иммуносупрессии: особенности этиологической диагностики

ПЕДИАТРИЯ

Екатерина Александровна Хузина Пермский государственный медицинский университет имени академика Е.А. Вагнера https://orcid.org/0000-0003-0901-7944
Евгений Григорьевич Фурман Пермский государственный медицинский университет имени академика Е.А. Вагнера https://orcid.org/0000-0002-1751-5532
Анастасия Алексеевна Кильдибекова Пермский государственный медицинский университет имени академика Е.А. Вагнера https://orcid.org/0009-0003-0918-0925

Ключевые слова:

pneumonia pharmacological immunosuppression etiology diagnosis children пневмония фармакологическая иммуносупрессия этиология диагностика дети

Аннотация

До настоящего времени в отношении пациентов с иммунодефицитными состояниями, индуцированными иммунобиологическими препаратами, нет определенного понимания, что именно приводит к иммуносупрессии у этих больных: первичное нарушение координации иммунных клеток или следствие фармакотерапии. Вместе с тем на сегодняшний день в связи со значительным прогрессом в терапии иммунопатологических заболеваний растет число изначально иммунокомпетентных пациентов, получающих различные биологические агенты: ингибиторы интерлейкина (ИЛ) -1, ИЛ-6, ИЛ-12/ИЛ-23, ингибиторы тирозинкиназы, В-лимфоцитарного фактора роста, костимулирующих молекул. Биологические препараты, вмешиваясь в процессы провоспалительных реакций, миграцию и активацию иммунных клеток, нарушают сигнальные пути, тем самым препятствуют иммунному ответу и увеличивают риск инфекции. Особенности течения инфекций нижних дыхательных путей у детей, получающих различные виды биологической иммуносупрессивной терапии, в настоящее время изучены недостаточно. В статье систематизированы литературные данные, позволяющие определить факторы риска и тактику этиологической диагностики у этой категории пациентов.

Биографии авторов

Екатерина Александровна Хузина, Пермский государственный медицинский университет имени академика Е.А. Вагнера

к.м.н., доцент кафедры факультетской и госпитальной педиатрии

Евгений Григорьевич Фурман, Пермский государственный медицинский университет имени академика Е.А. Вагнера

д.м.н., профессор, член-корреспондент РАН, заведующий кафедрой факультетской и госпитальной педиатрии, проректор по научной деятельности

Анастасия Алексеевна Кильдибекова, Пермский государственный медицинский университет имени академика Е.А. Вагнера

ординатор, кафедра факультетской и госпитальной педиатрии

Библиографические ссылки

1. Ma Y., Fan S., Xi J.S. Recent updates regarding the management and treatment of pneumonia in pediatric patients: a comprehensive review. Infection. 2025;53(6):2341–2359. https://doi.org/10.1007/s15010-025-02605-w.

2. Ullah N., Fusco L., Ametrano L., Bartalucci C., Giacobbe D.R., Vena A. et al. Diagnostic approach to pneumonia in immunocompromised hosts. J Clin Med. 2025;14(2):389. https://doi.org/10.3390/jcm14020389.

3. Murdaca G., Spanò F., Contatore M., Guastalla A., Penza E., Magnani O., Puppo F. Infection risk associated with anti-TNF-α agents: a review. Expert Open Drug Saf. 2015;14(4):571–582. https://doi.org/10.1517/14740338.2015.1009036.

4. Curtis J.R., Xie F., Yun H., Bernatsky S., Winthrop K.L. Real-world comparative risk of herpes virus infection in tofacitinib and biological-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847. https://doi.org/10.1136/annrheumdis-2016-209131.

5. Lachmann H.J., Lauwerys B., Miettunen P., Kallinich T., Jansson A., Rosner I. et al. Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: result from the CLUSTER trial. Clin Exp Rheumatol. 2021;39 (suppl 132):51–58. https://doi.org/10.55563/clinexprheumatol/e92f7o.

6. Yun H., Xie F., Delzell E., Levitan E.B., Chen L., Lewis J.D. et al. Comparative risk of hospitalized infections associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1):56–66. https://doi.org/10.1002/art.39399.

7. Wallace D.J., Navarra S., Petri M.A., Gallacher A., Thomas M., Furie R. et al.; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimimab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–154. https://doi.org/10.1177/0961203312469259.

8. Chen D.R., Cohen P.L. Living life without B cells: is repeated B-sell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumatol. 2012;7(2):159–166. https://doi.org/10.2217/ijr.12.7.

9. Kreitmann L., Helms J., Martin-Loeches I., Salluh J., Poulakou G., Pène F., Nseir S. ICU-acquired infection in immunocompromised patients. Intensive Care Med. 2024;50(3):332–349. https://doi.org/10.1007/s00134-023-07295-2.

10. Murali S., Marks A., Heeger A., Dako F., Febbo J. Pneumonia in the immunocompromised host. Semin Roentgenol. 2022;57(1):90–104. https://doi.org/10.1053/j.ro.2021.10.009.

11. Cheng G.S., Crothers K., Aliberti S., Bergeron A., Boeckh M., Chien J.W. et al. Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American thoracic Society Workshop Report. Ann Am Thorac Soc. 2023;20(3):341–353. https://doi.org/10.1513/ANNALSATS.202212-1019ST.

12. Di Pasquale M.F., Sotgiu G., Gramegna A., Radovanovic D., Terraneo S., Reyes L.F. et al.; GLIMP Investigators. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68(9): 1482–1493. https://doi.org/10.1093/cid/ciy723.

13. Anevlavis S., Bouros D. Community acquired bacterial pneumonia. Expert Opin Pharmacother. 2010;11(3):361–374. https://doi.org/10.1517/14656560903508770.

14. De la Calle C., Morata L., Cobos-Trigueros N., Martinez J.A., Cardozo C., Mensa J., Soriano A. Staphylococcus aureus bacteremic pneumonia. Eur J Microbiol Infect Dis. 2016;35(3):497–502. https://doi.org/10.1007/s10096-015-2566-8.

15. Restrepo M.I., Babu B.L., Reyes L.F., Chalmers J.D., Soni N.J., Sibila O. et al.; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalized patients. Eur Respir J. 2018;52(2):1701190. https://doi.org/10.1183/13993003.01190-2017.

16. Marrie T.J., Fine M.J., Obrosky D.S., Coley C., Singer D.E., Kapoor W.N. Community-acquired pneumonia due to Escherichia coli. Clin Microbiol Infect. 1998;4(12):717–723. https://doi.org/10.1111/j.1469-0691.1998.tb00657.x.

17. Reichel F., Tesch F., Berger S., Seifert M., Koschel D., Schmitt J., Kolditz M. Epidemiology and risk factors of community — acquired pneumonia in patients with different causes of immunosupression. Infection. 2024;52(6):2475–2486. https://doi.org/10.1007/s15010-024-02314-w.

18. Maschmeyer G., Carratalà J., Buchheidt D., Hamprecht A., Heussel C.P., Kahl C. et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogenic SCT excluded): Updated Guidelines of the Infection Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015;26(1):21–33. https://doi.org/10.1093/annonc/mdu192.

19. Harris A.M., Bramley A.M., Jain S., Arnold S.R., Ampofo K., Self W.H. et al. Influence of antibiotics on the detection of bacteria by culture- based and culture-independent diagnostic tests in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis. 2017;4(1):ofx014. https://doi.org/10.1093/ofid/ofx014.

20. Huang H.S., Tsai C.L., Chang J., Hsu T.C., Lin S., Lee C.C. Multiplex PCR system for the rapid diagnosis of respiratory viral infection: systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(10):1055–1063. https://doi.org/10.1016/j.cmi.2017.11.018.

21. Song J.Y., Eun B.W., Nahm M.H. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother. 2013;45(4):351–366. https://doi.org/10.3947/ic.2013.45.4.351.

22. Fukuyama H., Yamashiro S., Kinjo K., Tamaki H., Kishaba T. Validation of sputum Gram stain for treatment of community – acquired pneumonia and healthcare-associated pneumonia: a prospective observational study. BMC Infect Dis. 2014;14:534. https://doi.org/10.1186/1471-2334-14-534.

23. Zhang R., Wu Y., Deng G., Deng J. Value of sputum Gram strain, sputum culture, and bronchoalveolar lavage fluid Gram strain in predicting single bacterial pathogen among children with community-acquired pneumonia. BMC Pulm Med. 2022;22(1):427. https://doi.org/10.1186/s12890-022-02234-1.

24. Yasuo S., Murata M., Nakagawa N., Kawasaki T., Yoshida T., Ando K., Okamori S., Okada Y. Japanese ARDS clinical practice guideline systematic review task force diagnostic accuracy of urinary antigen tests for pneumococcal pneumonia among patients with acute respiratory failure suspected pneumonia: a systematic review and meta-analysis. BMJ Open. 2022;12(8):e057216. https://doi.org/10.1136/bmjopen-2021-057216.

25. Sordé R., Falcó V., Lowak M., Domingo E., Ferrer A., Burgos J. et al. A current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011;171(2):166–172. https://doi.org/10.1001/archinternmed.2010.347.

26. Gadsby N.J., Russell C.D., Mc Hugh M.P., Mark H., Conway Morris A., Laurenson I.F. et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817–823. https://doi.org/10.1093/cid/civ1214.

27. Kao A.S., Myer S., Wickrama M., Ismail R., Hettiarachchi M. Multidisciplinary management of Legionella disease in immunicompromised patients. Cureus. 2021;13(11):e19214. https://doi.org/10.7759/cureus.19214.

28. Viasus D., Gaia V., Manzur-Barbur C., Carratalà J. Legionnaires Disease: update on diagnosis and treatment. Infect Dis Ther. 2022;11(3):973–986. https://doi.org/10.1007/s40121-022-00635-7.

29. Kawasaki T., Nakagawa N., Murata M., Yasuo S., Yoshida T., Ando K. et al.; Japanese ARDS Clinical Practice Guideline Systematic Review Task Force. Diagnostic accuracy of urinary antigen tests for legionellosis: a systematic review and meta-analysis. Respir Investig. 2022;60(2):205–214. https://doi.org/10.1016/j.resinv.2021.11.011.

30. Sharma L., Losier A., Tolbert T., Dela Cruz C.S., Marion C.R. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clin Chest Med. 2017;38(11):45–48. https://doi.org/10.1016/j.ccm.2016.11.011.

31. Rouzaud C., Rodriguez-Nava V., Catherinot E., Méchaï F., Bergeron E., Farfour E. et al. Clinical assessment of a Nocardia PCR-based assay for diagnosis of nocardiosis. J Clin Microbiol. 2018;56(6):e00002-18. https://doi.org/10.1128/JCM.00002-18.

32. Lodha L., Mudliar S.R., Singh J., Maurya A., Khurana A.K., Khadanga S., Singh S. Diagnostic performance of multiplex PCR for detection of Mycobacterium tuberculosis complex in presumptive pulmonary tuberculosis patients and its utility in smear negative specimens. J Lab Physicians. 2022;14(4):403–411. https://doi.org/10.1055/s-0042-1757231.

33. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F. et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculosis mycobacterial disease. Am J Respir Crit Care Med. 2007;175(4):367–416. https://doi.org/10.1164/rccm.200604-571ST.

34. Ginocchio C.C., Zhang F., Manji R., Arora S., Bornfreund M., Falk L. et al. Evaluation of multiple test methods for the detection of the novel 2019 influenza A (H1N1) during the New York City outbreak. J Clin Virol. 2009;45(3):191– 195. https://doi.org/10.1016/j.jcv.2009.06.005.

35. Chartrand C., Tremblay N., Renaud C., Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738–3749. https://doi.org/10.1128/jcm.01816-15.

36. Saksirisampant G., Kawamatawong T., Promsombat K., Sukkasem W., Liamsombut S., Pasomsub E., Bruminhent J. A prospective study of plasma and bronchoalveolar lavage fluid CMV DNA load quantification for the diagnosis and outcome of CMV pneumonitis in immunocopromised hosts. J Clin Virol. 2022;155:105243. https://doi.org/10.1016/j.jcv.2022.105243.

37. Lindemans C.A., Leen A.M., Boelens J.J. How treat adenovirus in hematopoitic stem cell transplant recipients. Blood. 2010;116(25):5476–5485. https://doi.org/10.1182/blood-2010-04-259291.

38. Azoulay E., Russell L., Van de Louw A., Metaxa V., Bauer P., Povoa P. et al.; Nine-i Investigators. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 2020;46(2):298–314. https://doi.org/10.1007/s00134-019-05906-5.

39. Donnelly J.P., Chen S.C., Kauffman C.A., Steinbach W.J., Baddley J.W., Verweij P.E. et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for research and treatment of cancer and the Mycoses Study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376. https://doi.org/10.1093/cid/ciz1008.

40. Yamamura D., Xu J. Update on pulmonary cryptococcisis. Mycopathologia. 2021;186(5):717–728. https://doi.org/10.1007/s11046-021-00575-9.

41. Bassetti M., Giacobbe D.R., Agvald-Ohman C., Akova M., Alastruey-Izquierdo A., Arikan-Akdagli S. et al.; Study Group for Infections in Critically Ill Patients of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG), the European Society of Intensive Care Medicine (ESICM), the European Confederation of Medical Mycology (ECMM), the Mycoses Study Group Education and Research Consortium (MSGERC), the International Society of Antimicrobial Chemotherapy (ISAC), the International Society for Human and Animal Mycology (ISHAM), the Austrian Society for Medical Mycology (ÖGMM), the Italian Society of Anesthesia, Analgesia, Reanimation, and Intensive Care (SIAARTI), the Italian Society of Anti-Infective Therapy (SITA), and the FUNDICU Collaborators. Invasive Fungal Disease in adult patients in intensive care unit (FUNDICU): 2024 Consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAN. Intensive Care Med. 2024;50(4):502–515. https://doi.org/10.1007/s00134-024-07341-7.

42. Schroeder M., Simon M., Katchanov J., Wijaya C., Rohde H., Christner M. et al. Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study. Crit Care. 2016;20(1):139. https://doi.org/10.1186/s13054-016-1326-1.

43. Ogawa M., Hoshina T., Abushawish A., Kusuhara K. Evaluation of the usefulness of culture of induced sputum and the optimal timing for the collection of a good-quality sputum sample to identify causative pathogen of community – acquired pneumonia in young children: a prospective observational study. J Microbiol Immunol Infect. 2023;56(5):1036–1044. https://doi.org/10.1016/j.jmii.2023.05.005.

44. Li C., Sun L., Liu Y., Zhou H., Chen J., She M., Wang Y. Diagnostic value of bronchoalveolar lavage fluid galactomannan assay for invasive pulmonary aspergillosis in adults: a meta-analysis. J Clin Pharm Ther. 2022;47(12):1913–1922. https://doi.org/10.1111/jcpt.13792.

45. Leeflang M.M., Debets-Ossenkopp Y.J., Wang J., Visser C.E., Scholten R.J., Hooft L. et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015; 2015(12):CD007394. https://doi.org/10.1002/14651858.CD007394.pub2.

46. Mikulska M., Furfaro E., Del Bono V., Raiola A.M., Ratto S., Bacigalupo A., Viscoli C. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67(7):1746–1748. https://doi.org/10.1093/jac/dks111.

47. Fang W., Wu J., Cheng M., Zhu X., Du M., Chen C. et al. Diagnosis of invasive fungal infections: challenges and recent development. J Biomed Sci. 2023;30(1):42. https://doi.org/10.1186/s12929-023-00926-2.

48. Han Y., Wu X., Jiang G., Guo A., Jin Z., Ying Y. et al. Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnosis meta-analysis. BMC Pulm Med. 2023;23(1):58. https://doi.org/10.1186/s12890-023-02343-5.

49. Mengoli C., Cruciani M., Barnes R.A., Loeffler J., Donnelly J.P. Use PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89–96. https://doi.org/10.1016/S1473-3099(09)70019-2.

50. Del Corpo O., Butler-Laporte G., Sheppard D.C., Cheng M.P., Mc Donald E.G., Lee T.C. Diagnostic accuracy of serum (1,3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(9):1137–1143. https://doi.org/10.1016/j.cmi.2020.05.024.

51. Karageorgopoulos D.E., Qu J.M., Korbila I.P., Zhu Y.G., Vasileiou V.A., Falagas M.E. Accuracy of β-D-Glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19(1):39–49. https://doi.org/10.1111/j.1469-0691.2011.03760.x.

52. Liang B., Lin Z., Li J., Jiang R., Zhan W., Jian X. Diagnostic accuracy of cryptococcal antigen test in pulmonary cryptococcosis: a protocol for a systematic review and meta-analysis. BMJ Open. 2023;13(4):e070994. https://doi.org/10.1136/bmjopen-2022-070994.

53. Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A, Dannaoui E., Hochhegger B. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421. https://doi.org/10.1016/S1473-3099(19)30312-3.

54. Thomas C.F., Limper A.H. Pneumocystic pneumonia. N Engl J Med. 2004;350(24):2487–2498. https://doi.org/10.1056/NEJMra032588.

55. Lu Y., Ling G., Qiang C., Ming Q., Wu C., Wang K., Ying Z. PCR diagnosis of pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol. 2011;49(12):4361–4363. https://doi.org/10.1128/JCM.06066-11.

56. Meya D.B., Willamson P.R. Cryptococcal disease in diverse hosts. N Engl J Med. 2024;390(17):1597–1610. https://doi.org/10.1056/NEJMra2311057.

57. Gago S., Esteban C., Valero C., Zaragoza O., Puig de la Bellacasa J., Buitrago M.J. Multiplex real-time PCR assay for identification of Pneumocystis jirovecii, Histoplasma capsulatum, and Cryptococcus neoformans /Cryptococcus gattii in samples from AIDS patients with opportunistic pneumonia. J Clin Microbiol. 2014;52(4):1168–1176. https://doi.org/10.1128/JCM.02895-13.

58. Skiada A., Lass-Floerl C., Klimko N., Ibrahim A., Roilides E., Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93–101. https://doi.org/10.1093/mmy/myx101.

59. Ino K., Nakase K., Nakamura A., Nakamori Y., Sugawara Y., Miyazaki K. et al. Management of pulmonary mucormycosis based on a polymerase chain reaction (PCR) diagnosis in patients with hematologic malignancies: a report of four cases. Intern Med. 2017;56:707–711. https://doi.org/10.2169/internalmedicine.56.7647.

60. Коротаева К.С., Фурман Е.Г., Сумливая О.Н. Интегральные показатели лейкоцитарной формулы у детей с коронавирусной инфекцией COVID-19. Пермский медицинский журнал. 2022;39(1):27–34. https://doi.org/10.17816/pmj39127-34. Korotaeva K.S., Furman E.G., Sumlivaya O.N. Integral leukocgram indices in children with coronavirus infection COVID-19. Perm Medical Journal. 2022;39(1):27–34. (In Russ.). https://doi.org/10.17816/pmj39127-34.

Пневмонии на фоне фармакологической иммуносупрессии: особенности этиологической диагностики: ПЕДИАТРИЯ. (2026). Children’s Medicine of the North-West, 14(2), 76-89. https://doi.org/10.56871/

Скачать ссылку

Как цитировать

Пневмонии на фоне фармакологической иммуносупрессии: особенности этиологической диагностики: ПЕДИАТРИЯ. (2026). Children’s Medicine of the North-West, 14(2), 76-89. https://doi.org/10.56871/

Скачать ссылку